RAPID-TnT随机对照试验的晚期结局:疑似ACS的0/1小时高敏肌钙蛋白T方案
RAPID-TnT多中心前瞻性随机试验纳入3378例疑似急性冠脉综合征且无缺血性心电图表现的患者,比较非盲法0/1小时高敏肌钙蛋白T(报告至<5 ng/L)与盲法0/3小时方案(报告至≤29 ng/L)。12个月随访显示两组全因死亡或心肌梗死无总体差异,但在初始肌钙蛋白T≤29 ng/L者中非盲法报告与死亡或心梗增加相关。
要点
- 非盲法0/1小时hs-cTnT方案未减少12个月缺血事件。
- 初始hs-cTnT≤29 ng/L者中非盲法报告与死亡或心梗增加相关。
- 非盲法0/1小时方案与功能检查减少相关,但冠脉造影无总体差异。
核心结论
- 非盲法0/1小时hs-cTnT报告方案未减少12个月缺血事件。
- 在初始hs-cTnT≤29 ng/L的患者中,非盲法报告与死亡或心肌梗死增加相关。
研究设计与样本
- 多中心前瞻性患者层面随机对照试验,比较非盲法0/1小时hs-cTnT方案与盲法0/3小时hs-cTnT标准实践。
- 2015年8月至2019年4月随机3378例,108例退出,3270例完成12个月随访(盲法组1632例,非盲法组1638例)。
主要发现
- 12个月全因死亡或心肌梗死:非盲法组82/1638(5.0%),盲法组62/1632(3.8%),HR 1.32(95%CI 0.95-1.83),P=0.10。
- 初始hs-cTnT≤29 ng/L者中,非盲法组死亡或心肌梗死55/1507(3.7%),盲法组34/1486(2.3%),HR 1.60(95%CI 1.05-2.46),P=0.030。
- 12个月侵入性冠脉造影:非盲法组232/1638(14.2%),盲法组202/1632(12.4%),P=0.13;在hs-cTnT处于盲法报告范围内的患者中,非盲法组168/1507(11.2%),盲法组124/1486(8.3%),P=0.010。
- 非盲法0/1小时hs-cTnT方案与功能检查减少相关。
- 2993/3270(91.5%)初始肌钙蛋白浓度≤29 ng/L。
临床怎么用
- 采用0/1小时hs-cTnT方案时,需关注非盲法报告低浓度肌钙蛋白可能带来的死亡和心肌梗死风险。
- 对初始hs-cTnT≤29 ng/L的患者,非盲法报告与缺血事件增加相关,临床决策应谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-sensitivity troponin assays are increasingly being adopted to expedite evaluation of patients with suspected acute coronary syndromes. Few direct comparisons have examined whether the enhanced performance of these assays at low concentrations leads to changes in care that improves longer-term outcomes. This study evaluated late outcomes of participants managed under an unmasked 0/1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol compared with a 0/3-hour masked hs-cTnT protocol. METHODS: We conducted a multicenter prospective patient-level randomized comparison of care informed by unmasked 0/1-hour hs-cTnT protocol (reported to <5 ng/L) versus standard practice masked hs-cTnT testing (reported to ≤29 ng/L) assessed at 0/3 hours and followed participants for 12 months. Participants included were those presenting to metropolitan emergency departments with suspected acute coronary syndromes, without ECG evidence of coronary ischemia. The primary end point was time to all-cause death or myocardial infarction using Cox proportional hazards models adjusted for clustering within hospitals. RESULTS: Between August 2015 and April 2019, we randomized 3378 participants, of whom 108 withdrew, resulting in 12-month follow-up for 3270 participants (masked: 1632; unmasked: 1638). Among these, 2993 (91.5%) had an initial troponin concentration of ≤29 ng/L. Deployment of the 0/1-hour hs-cTnT protocol was associated with reductions in functional testing. Over 12-month follow-up, there was no difference in invasive coronary angiography (0/1-hour unmasked: 232/1638 [14.2%]; 0/3-hour masked: 202/1632 [12.4%]; P=0.13), although an increase was seen among patients with hs-cTnT levels within the masked range (0/1-hour unmasked arm: 168/1507 [11.2%]; 0/3-hour masked arm: 124/1486 [8.3%]; P=0.010). By 12 months, all-cause death and myocardial infarction did not differ between study arms overall (0/1-hour: 82/1638 [5.0%] versus 0/3-hour: 62/1632 [3.8%]; hazard ratio, 1.32 [95% CI, 0.95-1.83]; P=0.10). Among participants with initial troponin T concentrations ≤29 ng/L, unmasked hs-cTnT reporting was associated with an increase in death or myocardial infarction (0/1-hour: 55/1507 [3.7%] versus 0/3-hour: 34/1486 [2.3%]; hazard ratio, 1.60 [95% CI, 1.05-2.46]; P=0.030). CONCLUSIONS: Unmasked hs-cTnT reporting deployed within a 0/1-hour protocol did not reduce ischemic events over 12-month follow-up. Changes in practice associated with the implementation of this protocol may be associated with an increase in death and myocardial infarction among those with newly identified troponin elevations. Registration: URL: https://www.anzctr.org.au; Unique identifier: ACTRN12615001379505.
引用
- Lambrakis K, Papendick C, French JK, et al. Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS. Circulation. 2021. PMID: 33998255. doi:10.1161/CIRCULATIONAHA.121.055009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。